Lakewood-Amedex Seeks Shareholder Nod for 8x Authorized Share Hike and Reverse Split Authority

summarizeSummary

Lakewood-Amedex's definitive proxy seeks shareholder approval for an 8x increase in authorized common shares to 100M and grants the board broad reverse split authority through 2027, signaling potential for massive dilution as the company fights to maintain its Nasdaq listing amid ongoing financial distress.

check_boxKey Events · Corporate Governance and Compliance · LABT

• 8x Authorized Share Increase Proposed

  Proposal 2 seeks to boost authorized common shares from 12.5M to 100M, creating ~97.4M unissued shares — an 8x increase that, if fully utilized, would dilute existing holders by over 40x based on the current 2.37M shares outstanding.

• Blanket Reverse Split Authority Sought

  Proposal 3 asks shareholders to grant the board discretion to execute one or more reverse splits at a cumulative ratio up to 1:20 through September 22, 2027, primarily to maintain Nasdaq's $1 minimum bid price, following a 1-for-10 reverse split just two months ago.

• Equity Plan Share Reserve Expansion

  Proposal 4 would increase the 2020 Equity Incentive Plan share reserve from 183,505 to 400,000 shares, a 118% increase, enabling additional stock-based compensation that could further dilute existing shareholders.

• Related Party Loans Highlight Cash Crunch

  The proxy discloses $198,158 in short-term promissory notes issued in early 2026 to a board member ($93,158), existing shareholders, and a third party, plus $1.5M in convertible notes from insiders that converted upon Nasdaq listing, underscoring the company's dependence on insider financing.

auto_awesomeAnalysis · LABT · Life Sciences

Lakewood-Amedex's definitive proxy sets a September 22 meeting to vote on a massive authorized share increase from 12.5M to 100M shares — an 8x jump that, combined with the existing 2.37M shares outstanding, creates headroom for extreme dilution. The board also seeks blanket authority to execute reverse splits up to 1:20 through September 2027, a tool to maintain Nasdaq's $1 minimum bid but one that could further concentrate value destruction. These proposals come just months after a 1-for-10 reverse split in June 2026 and a highly dilutive Series C financing, against a backdrop of going concern warnings and a sub-$6M market cap. The equity plan amendment to 400,000 shares adds another layer of potential dilution. The filing also discloses related party loans from directors and shareholders, including a $93,158 note from a board member, underscoring the company's reliance on insider financing to stay afloat.